ASH 2023: Using Measurable Residual Disease to Guide Ibrutinib-Venetoclax Treatment Length Aids Outcomes in Chronic Lymphocytic Leukemia
Authors report that personalized treatment length is associated with improved progression-free and overall survival
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.